Rishi Sury Kotecha

The paper uses mass spectrometry to profile histone post-translational modifications in T-ALL cell lines and identifies drug response signatures, but finds discrepancies between in vitro and in vivo models.

This study identifies PRAME as a therapeutic target in NUT carcinoma, showing its high expression and susceptibility to T-cell mediated cytotoxicity via PRAME epitopes presented by HLA Class I molecules.

This paper identifies I3IN-002, a small molecule inhibitor of IGF2BP3, which shows anti-leukemic activity in cell lines and a mouse model.

This study investigates age-dependent tumor-immune interactions in pediatric cancer using mouse models and patient samples, finding that pediatric tumors have distinct immune profiles and poor response to immunotherapy, which can be improved by modulating the tumor microenvironment.